Keywords: genentech, curtail, off-label, avastin, use, effort, combat

Genentech to curtail off-label Avastin use

Article | 22 October 2007

Print This

In an effort to combat the off-label use of its anticancer drug Avastin (bevacizumab) in the treatment of wet age-related ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in